QOL-DN has also been shown to be a reliable indicator of the impact on QOL of symptomatic peripheral neuropathy experienced by patients with V30M Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) (61) In the Tafamadis study, Coelho and colleagues (62, 63) demonstrated that treatment of patients with TTR-FAP was associated with an improvement of Norfolk QOL scores of symptoms and activities of daily living in parallel with improved NIS-LL, supporting the notion that the QOL tool can be nerve fiber specific. The gene discussed is TTR; the disease is liver dysplastic nodule.